Skip to main content

Arcturus Therapeutics Holdings Inc (ARCT) Stock

Arcturus Therapeutics Holdings Inc Stock Details, Movements and Public Alerts

Stock Details

Arcturus Therapeutics Holdings Inc (ARCT), a prominent company in the healthcare sector within the biotechnology industry, is based in USA and primarily trades on the NASDAQ.Currently, the stock is trading at $8.72. Over the past 52 weeks, it has ranged between $7.93 and $24.17. This places the current price at 36.1% of its 52-week high and 10.0% above its 52-week low. Recent trading volume was recorded at 1,154,743. The 14-day Relative Strength Index (RSI) stands at 30.23, suggesting neutral conditions. The stock is currently trading below its 50-day moving average of $17.08 by 48.95%. Similarly, it is below its 200-day moving average of $14.55 by 40.07%. The MACD histogram is -0.45, indicating bearish momentum (MACD Line: -2.89, Signal Line: -2.44). There are currently 3 active alerts set for ARCT by users.

52-Week Range

$24.17 - $7.93

-63.92% from high · +9.96% from low

Avg Daily Volume

2,202,077

20-day average

100-day avg: 951,937

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Forward P/E

2.48

Price to Book

2.57

EV/EBITDA

-25.67

EPS (TTM)

-$2.22

Price to Sales

1.94

Beta

2.07

More volatile than market

How is ARCT valued relative to its earnings and growth?
Valuation data is not available for this stock.
What is ARCT's risk profile compared to the market?
With a beta of 2.07, Arcturus Therapeutics Holdings Inc is significantly more volatile than the market. For every 10% market move, this stock tends to move 21% in the same direction. Higher beta stocks offer greater potential returns but with increased risk. The price-to-book ratio of 2.57 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

-49.30%

Operating Margin

-41.00%

EBITDA

$-69,262,000

Return on Equity

-24.60%

Return on Assets

-13.00%

Revenue Growth (YoY)

-43.20%

Earnings Growth (YoY)

0.00%

How profitable and efficient is ARCT's business model?
Arcturus Therapeutics Holdings Inc achieves a profit margin of -49.30%, meaning it retains $-49.30 from every $100 in revenue after all expenses. This relatively low margin suggests the company operates in a competitive environment or high-cost industry where profitability is challenging. The operating margin of -41.00% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at -24.60% and ROA at -13.00%, the company achieves moderate returns on invested capital.
What are ARCT's recent growth trends?
Arcturus Therapeutics Holdings Inc's revenue declined by 43.20% year-over-year, indicating challenges in maintaining sales momentum. This contraction may reflect market headwinds, competitive pressures, or strategic transitions.0 These growth metrics should be evaluated against BIOTECHNOLOGY industry averages for proper context.

Company Size & Market

Market Cap

$236.8M

Revenue (TTM)

$122.12M

Revenue/Share (TTM)

$4.51

Shares Outstanding

27.15M

Book Value/Share

$8.51

Asset Type

Common Stock

What is ARCT's market capitalization and position?
Arcturus Therapeutics Holdings Inc has a market capitalization of $236.8M, classifying it as a small-cap stock (under $2B). Small-caps offer significant growth potential but come with higher volatility and risk. They can be more sensitive to economic conditions but may provide outsized returns if successful. With 27.15M shares outstanding, the company's ownership is relatively concentrated. As a participant in the BIOTECHNOLOGY industry, it competes with other firms in this sector.
How does ARCT's price compare to its book value?
Arcturus Therapeutics Holdings Inc's book value per share is $8.51, while the current stock price is $8.72, resulting in a price-to-book (P/B) ratio of 1.02. This reasonable premium to book value suggests the market values the company's earnings power and intangible assets appropriately. Most profitable companies trade between 1-3x book value. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$44.75

413.19% upside potential

Analyst Recommendations

Strong Buy

3

Buy

8

Hold

0

Sell

0

Strong Sell

0

How reliable are analyst predictions for ARCT?
11 analysts cover ARCT with 100% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $44.75 implies 413.2% upside, but targets are often adjusted to follow price moves rather than predict them.
What is the Wall Street consensus on ARCT?
Current analyst recommendations:3 Strong Buy, 8 Buy, 000The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Nov 8, 2025, 09:12 AM

Technical Indicators

RSI (14-day)

30.23

Neutral

50-Day Moving Average

$17.08

-48.95% below MA-50

200-Day Moving Average

$14.55

-40.07% below MA-200

MACD Line

-2.89

MACD Signal

-2.44

MACD Histogram

-0.45

Bearish

What does ARCT's RSI value tell investors?
The RSI (Relative Strength Index) for ARCT is currently 30.23, indicating the stock is showing bearish momentum (30-40 range). Selling pressure is evident but not extreme. This often occurs during pullbacks in uptrends or early stages of downtrends. Combined with the price being below the 50-day moving average, this confirms bearish conditions.
How should traders interpret ARCT's MACD and moving average crossovers?
MACD analysis shows the MACD line at -2.89 below the signal line at -2.44, with histogram at -0.45. This bearish crossover indicates downward pressure. The 50-day MA ($17.08) is above the 200-day MA ($14.55), forming a golden cross pattern that typically signals a long-term uptrend. Price is currently below both MAs, confirming weakness.

Indicators last updated: Nov 9, 2025, 12:33 AM

Active Alerts

Alert Condition
Volume change
Threshold
150%
Created
Nov 8, 2025, 09:13 AM
Alert Condition
Forward P/E falls below
Threshold
2.43 x
Created
Nov 8, 2025, 09:13 AM
Alert Condition
RSI Threshold Cross
Threshold
30
Created
Nov 8, 2025, 09:13 AM

Stay Ahead of the Market with Arcturus Therapeutics Holdings Inc Alerts

Set up price alerts for Arcturus Therapeutics Holdings Inc and get notified instantly when the price hits your target. Never miss an important price movement again.